Changes in Hong Kong stocks | Zhaoyan New Pharmaceutical (06127) rose more than 4% in early trading, and the security assessment industry soared in volume and price, and scarce high-quality monkey resources benefited significantly

Zhitongcaijing · 5d ago

The Zhitong Finance App learned that Zhaoyan New Pharmaceutical (06127) rose more than 4% in early trading. As of press release, it rose 2.01% to HK$24.42, with a turnover of HK$64,105 million.

According to the news, according to a report by the Financial Federation, the reporter recently learned from two breeding companies in Wuhan and Guangzhou as a purchaser that not only do prices continue to rise in the domestic experimental monkey market, but there are also supply shortages for commercial monkeys in some age groups. As demand for innovative drug development picks up and AI pharmaceutical amplification test orders, the demand for non-human primate experimental animals continues to increase in preclinical research.

Changjiang Securities released a research report saying that the trend of sharp rise in volume and price in the security assessment industry is quite clear, and the company has scarce high-quality monkey resources or has benefited significantly. China Post Securities pointed out that fair value returns from biological assets have converged, and the profit structure has returned to the main business. Net income from changes in the fair value of biological assets in the first three quarters was 866 million yuan, but at the pace, the share of contributions from the main business continued to increase as the rise in monkey prices slowed down. The dependence of performance on revaluation of monkey prices declined markedly, and profit quality improved.